Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q2

2342.TEDINET S100S7OP
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥11.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥5.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥135m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥199m2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥204m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥157m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥410m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥55m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥55m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥10.5bnat 2023-09-30Cons.Assets
Total assets¥10.7bnat 2023-03-31Cons.Assets
Total assets¥10.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥4.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥6.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥6.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥696m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥216m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥601m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥485m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥65m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.762023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.322022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3.262022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 32
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥111m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥153m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥187,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥92m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥246m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 493
ItemContextValueUnit
Other caPrior1YearInstant788761000JPY
Other caCurrentQuarterInstant363300000JPY
Allowance for doubtful accounts caPrior1YearInstant-7566000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-7942000JPY
Current assetsPrior1YearInstant7562372000JPY
Current assetsCurrentQuarterInstant7267805000JPY
Buildings and structures netPrior1YearInstant980931000JPY
Buildings and structures netCurrentQuarterInstant1032317000JPY
LandPrior1YearInstant905846000JPY
LandCurrentQuarterInstant905846000JPY
Other net ppePrior1YearInstant104883000JPY
Other net ppeCurrentQuarterInstant158861000JPY
Property plant and equipmentPrior1YearInstant1991661000JPY
Property plant and equipmentCurrentQuarterInstant2097025000JPY
GoodwillPrior1YearInstant557250000JPY
GoodwillCurrentQuarterInstant534769000JPY
Other iaPrior1YearInstant10422000JPY
Other iaCurrentQuarterInstant12087000JPY
Intangible assetsPrior1YearInstant567673000JPY
Intangible assetsCurrentQuarterInstant546856000JPY
Investment securitiesPrior1YearInstant105502000JPY
Investment securitiesCurrentQuarterInstant135750000JPY
Other ioaPrior1YearInstant469281000JPY
Other ioaCurrentQuarterInstant458599000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-23559000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-23559000JPY
Investments and other assetsPrior1YearInstant551223000JPY
Investments and other assetsCurrentQuarterInstant570790000JPY
Noncurrent assetsPrior1YearInstant3110559000JPY
Noncurrent assetsCurrentQuarterInstant3214672000JPY
AssetsPrior1YearInstant10672931000JPY
AssetsCurrentQuarterInstant10482478000JPY
Accounts payable tradePrior1YearInstant408742000JPY
Accounts payable tradeCurrentQuarterInstant643260000JPY
Accounts payable otherPrior1YearInstant284024000JPY
Accounts payable otherCurrentQuarterInstant299617000JPY
Short term loans payablePrior1YearInstant170000000JPY
Short term loans payableCurrentQuarterInstant490000000JPY
Current portion of bondsPrior1YearInstant14000000JPY
Current portion of bondsCurrentQuarterInstant14000000JPY
Current portion of long term loans payablePrior1YearInstant478032000JPY
Current portion of long term loans payableCurrentQuarterInstant460518000JPY
Income taxes payablePrior1YearInstant57378000JPY
Income taxes payableCurrentQuarterInstant27741000JPY
Advances receivedPrior1YearInstant969958000JPY
Advances receivedCurrentQuarterInstant619441000JPY
Provision for bonusesPrior1YearInstant23388000JPY
Provision for bonusesCurrentQuarterInstant68312000JPY
Provision for loss on order received clPrior1YearInstant63000JPY
Provision for loss on order received clCurrentQuarterInstant63000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass